<DOC>
	<DOCNO>NCT01224652</DOCNO>
	<brief_summary>The primary objective study compare efficacy paclitaxel monotherapy irinotecan monotherapy define progression-free survival ( PFS ) , patient recurrent metastatic gastric cancer progress follow first line therapy .</brief_summary>
	<brief_title>Efficacy Study Paclitaxel Versus Irinotecan Patients With Recurrent Metastatic Gastric Cancer Who Progress Following First-line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm gastric adenocarcinoma tissue/cell Recurrent metastatic gastric cancer progress follow first line therapy Patients must ≥18 year age . ECOG performance status ≤ 2 At least one lesion ( measurable nonmeasurable evaluable ) accord RECIST criterion Normal organ bone marrow function measure within 2 week prior administration study treatment define : Haemoglobin ≥ 9.0 g/dL White blood cell ( WBC ) ≥ 3000/µL Absolute neutrophil count ( ANC ) ≥ 1500/µL Platelet count ≥ 100 x 103/µL Total bilirubin ≤ 1.5 x upper normal limit ( UNL ) Creatinine clearance ≥ 60 ml/min Serum creatinine ≤ 1.5 x UNL AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x UNL unless liver metastasis present case must ≤ 5x UNL Life expectancy ≥ 12 week . Written inform consent Provision inform consent genetic research ( In case optional genetic research ) More one prior chemotherapy regimen treatment gastric cancer metastatic recurrent set . Treatment investigational product last 14 day ( long period depend defined characteristic agent use ) . Any previous treatment taxane , include paclitaxel docetaxel irinotecan , metastatic recurrent set . Patients second primary cancer , except : adequately treat non melanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease ≥5 year . Patients receive systemic chemotherapy , radiotherapy ( except palliative reason ) , within 2 week last dose prior study treatment ( long period depend defined characteristic agent use ) . Ongoing toxicity ( &gt; CTCAE grade 2 ) cause previous cancer therapy . Clinically proven gastric outlet obstruction CTCAE grade 3 grade 4 upper GI bleed Medically uncontrolled , clinically significant heart disease infection Patients symptomatic uncontrolled brain metastasis . Major surgery within 2 week start study treatment patient must recover effect major surgery . Women pregnancy potential willing pregnant . Pregnant breastfeed woman . Others Poor medical risk due serious , uncontrolled medical disorder , non malignant systemic disease active , uncontrolled infection Any psychiatric disorder prohibits obtain informed consent regular followup . Inappropriate patient subject study investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>irinotecan</keyword>
</DOC>